New hope for rare melanoma? small trial tests PLX3397

NCT ID NCT02975700

Completed Disease control Sponsor: Daiichi Sankyo Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 21, 2026 · Last updated May 25, 2026 · Updated 15 times

Summary

This early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific genetic change (KIT mutation) and cannot be removed by surgery. The main goals were to see if the drug is safe and whether it can shrink tumors. The study was completed, but results were limited due to the very small number of participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Samsung Medical Center

Seoul, Gangnam-Gu, 06351, South Korea
Seoul National University Hospital

Seoul, South Korea
Severance Hospital, Yonsei University Health System

Seoul, Seodaemun-gu, 03722, South Korea
Sun Yat-sen Hospital

Guangzhou, Guangdong, China

Conditions

Explore the condition pages connected to this study.

MELANOMA